Barrow Hanley Mewhinney & Strauss LLC Sells 100,740 Shares of Smith & Nephew plc (NYSE:SNN)

Barrow Hanley Mewhinney & Strauss LLC lessened its stake in Smith & Nephew plc (NYSE:SNN - Free Report) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,181,330 shares of the medical equipment provider's stock after selling 100,740 shares during the period. Barrow Hanley Mewhinney & Strauss LLC owned about 0.96% of Smith & Nephew worth $103,613,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its position in shares of Smith & Nephew by 75.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,227 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 526 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Smith & Nephew by 150.9% in the 4th quarter. Parallel Advisors LLC now owns 1,533 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 922 shares in the last quarter. Mather Group LLC. lifted its position in shares of Smith & Nephew by 9,735.3% during the 2nd quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 1,655 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Smith & Nephew by 1,894.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,735 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 1,648 shares in the last quarter. Finally, Principal Securities Inc. acquired a new stake in Smith & Nephew in the fourth quarter worth $52,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. UBS Group upgraded shares of Smith & Nephew from a "neutral" rating to a "buy" rating in a report on Wednesday, June 5th. Deutsche Bank Aktiengesellschaft began coverage on Smith & Nephew in a research note on Wednesday, July 24th. They set a "buy" rating on the stock. Finally, StockNews.com raised Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy".

Smith & Nephew Stock Performance

Shares of NYSE SNN traded down $0.38 during mid-day trading on Friday, reaching $30.57. 561,533 shares of the company's stock traded hands, compared to its average volume of 876,157. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $30.09 and a 200 day simple moving average of $27.09. Smith & Nephew plc has a 1-year low of $21.52 and a 1-year high of $31.72.

Smith & Nephew Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 4th will be paid a dividend of $0.288 per share. The ex-dividend date of this dividend is Friday, October 4th. This is an increase from Smith & Nephew's previous dividend of $0.24.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.